Goldman Sachs
DMRA

Goldman Sachs’s Damora Therapeutics DMRA Stock Holding History

Goldman Sachs’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83M Buy
339,379
+251,043
+284% +$6.08M ﹤0.01% 3356
2026
Q1 		$2.29M Buy
+88,336
New +$2.27M ﹤0.01% 4423
2021
Q2 		– Sell
-536
Closed -$81K – 6324
2021
Q1 		$81K Buy
+536
New +$146K ﹤0.01% 5880

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Goldman Sachs's DMRA Position: Q2 2026 in Review

Goldman Sachs increased its Damora Therapeutics (DMRA) stake by 284% in Q2 2026, buying an estimated $6.08M and bringing the position to 339,379 shares worth $8.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3356.

Goldman Sachs first reported a position in DMRA in Q1 2021 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Goldman Sachs held 339,379 shares of Damora Therapeutics worth $8.83M as of Q2 2026.
  • Goldman Sachs bought 251,043 Damora Therapeutics shares in Q2 2026, an estimated $6.08M.
  • Damora Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3356 holding.
  • Goldman Sachs first reported a position in Damora Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.